MAOA and Parkinson disease: These results are consistent with our data showing a trend of dose‐dependent inhibition of MAO‐A in patients with PD, in agreement with previous data that nilotinib reduces dopamine catabolism in mice4, 6 and human.17, 18, 19, 20